Clearmind Medicine Gets US Patent for Binge Behavior Treatment
Ticker: CMND · Form: 6-K · Filed: Aug 21, 2024 · CIK: 1892500
Sentiment: bullish
Topics: patent, pharmaceutical, mental-health, treatment
Related Tickers: CMND
TL;DR
CMND just got a US patent for treating binge eating/drinking with MEAI. Big win for their drug pipeline.
AI Summary
Clearmind Medicine Inc. announced on August 21, 2024, that it has received U.S. patent approval for its treatment of binge behavior. This patent, number 11,994,008, covers the use of MEAI as a therapeutic agent for treating binge eating disorder and binge drinking. The company's stock is traded under the ticker CMND on the Nasdaq.
Why It Matters
This patent approval is a significant step for Clearmind Medicine, potentially validating their therapeutic approach and opening doors for future commercialization and partnerships in the mental health sector.
Risk Assessment
Risk Level: medium — The company is a clinical-stage biopharmaceutical company, and the success of its patented treatment is not yet proven in widespread clinical application.
Key Numbers
- 11,994,008 — US Patent Number (Granted for MEAI treatment of binge behavior)
Key Players & Entities
- Clearmind Medicine Inc. (company) — Registrant
- August 21, 2024 (date) — Announcement date
- 11,994,008 (patent_number) — Granted US patent number
- MEAI (drug_name) — Therapeutic agent
- binge eating disorder (medical_condition) — Treated condition
- binge drinking (medical_condition) — Treated condition
- CMND (ticker) — Nasdaq ticker symbol
- Nasdaq (exchange) — Stock exchange
FAQ
What specific binge behaviors does the patent cover?
The patent covers the use of MEAI as a therapeutic agent for treating binge eating disorder and binge drinking.
When was the patent granted?
The patent was granted on August 21, 2024.
What is the ticker symbol for Clearmind Medicine Inc.?
The ticker symbol is CMND, traded on the Nasdaq.
What is the active ingredient in the patented treatment?
The active ingredient is MEAI.
What form type is this filing?
This filing is a Form 6-K.
Filing Stats: 260 words · 1 min read · ~1 pages · Grade level 10.7 · Accepted 2024-08-21 16:12:02
Filing Documents
- ea0212020-6k_clearmind.htm (6-K) — 12KB
- ea021202002ex99-1_clearmind.htm (EX-99.1) — 11KB
- ex99-1_001.jpg (GRAPHIC) — 2KB
- 0001213900-24-071454.txt ( ) — 27KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Clearmind Medicine, Inc. (Registrant) Date: August 21, 2024 By: /s/ Adi Zuloff-Shani Name: Adi Zuloff-Shani Title: Chief Executive Officer 3